Loading…
Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.
Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.
Sells its own patented drugs mainly to hospitals, so a drug's place on China's national reimbursement list is what turns approval into volume. Its lymphoma drug has also been licensed to partners for markets outside China.
In one line: A small, China-only Incyte.
Moat: narrow (IP / patents). Patent-protected first-in-class molecules discovered in-house rather than licensed-in generics.
Headquarters: Shenzhen, China · Founded: 2001 · Employees: 1,002
Size Shenzhen Chipscreen Biosciences (688321.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.40B, the 1733rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥21.12 on 6 Nov 2026.
Performance Over six months the shares fell 32.6%, against -15.7% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 26.8% over the last twelve months (peer median +17.1%); the operating margin is 11.7% (peer median 3.7%).
Valuation It trades at 71.6× forward earnings against a peer median of 15.2× (2nd most expensive of 11).
Capital Return on invested capital runs 4.7 points below its cost of capital (9.6% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.08B | CN¥908M | CN¥656M | CN¥516M | CN¥528M |
| Revenue growth | — | +38% | +27% | -2% | — |
| Gross profit | CN¥969M | CN¥765M | CN¥544M | CN¥434M | CN¥475M |
| EBITDA | n/a | CN¥155M | CN¥899,100 | -CN¥138M | CN¥48.3M |
| Net income | CN¥71.4M | CN¥51.0M | -CN¥115M | CN¥88.8M | CN¥17.5M |
| Free cash flow | -CN¥134M | -CN¥62.8M | -CN¥179M | -CN¥372M | -CN¥351M |
| Capital expenditure | CN¥321M | CN¥179M | CN¥268M | CN¥229M | CN¥400M |
| Total debt | CN¥1.46B | CN¥1.67B | CN¥1.46B | CN¥1.20B | CN¥1.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences 688321.SS | $1.40B | -33% | +27% | 12% | 71.6× | n/a |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| BeOne Medicines 688235.SS | $45.8B | +19% | +28% | 15% | 74.5× | 23.3% |
| HUTCHMED (China) 0013.HK | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688321.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.2% | -6.4% | 5th lowest of 21 |
| 6-month return | -32.6% | -15.7% | 4th lowest of 21 |
| Distance from 52-week high | -42.1% | -40.2% | 11th highest of 21 |
| Revenue growth (TTM) | +26.8% | +17.1% | 6th highest of 18 |
| Operating margin | 11.7% | 3.7% | 7th highest of 18 |
| Forward P/E | 71.6× | 15.2× | 2nd most expensive of 11 |
| ROIC minus cost of capital | -4.7 pp | -4.7 pp | 9th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |